Issue Life sciences: from conglomerate to orchestrated Bioweave

Summary

This issue applies the superfluid enterprise idea to life sciences, where EY says the vertically integrated conglomerate is giving way to orchestrated networks. Bringing one new product to market already involves working with more than 30 partner organizations, and EY expects this to increase. Future leaders are therefore expected to coordinate complex, distributed networks spanning research, supply chains and commercialization. EY calls this future ecosystem the Bioweave. Sharing data, long held back by regulation and industry culture, is expected to become essential for business models that yield richer clinical insight and leaner operations. The shift implies that competitive strength will rest more on orchestration than on owning every capability.